Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis.

CONCLUSION: Our data support the view that single-agent treatment with an RAF inhibitor reduces disease activity but does not cure LCH.
PMID: 30474648 [PubMed - as supplied by publisher]

Source: Pediatric Research - November 24, 2018 Category: Pediatrics Authors: Schwentner R, Kolenová A, Jug G, Schnöller T, Ahlmann M, Meister B, Lehrnbecher T, Minkov M, Hutter C Tags: Pediatr Res Source Type: research